Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trialWilliam Camu, Gilbert Bensimon, Andrea Malaspina et al.|EBioMedicine|2020Cited by 81
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, Massimo Locati, P. Nigel Leigh et al.|The Lancet|2025Cited by 33
Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2Ilaria Giovannelli, Janine Kirby, Nadhim Bayatti et al.|Brain Communications|2021Cited by 28
Pharmacometabolomics applied to low‐dose interleukin‐2 treatment in amyotrophic lateral sclerosisHugo Alarcan, Hélène Blasco, Clément Bruno et al.|Annals of the New York Academy of Sciences|2024Cited by 6